Coumadin Alternative for Atrial Fibrillation
(2003) Last month’s American College of Cardiology conference finally has a proven alternative to Coumadin (see abstract below), in this case, given for Atrial Fibrillation patients. Please try to digest this attached information as some patients may finally get off Coumadin and onto a safer and more effective drug.
Very few patients are willing to bet their life on just the Endozym (with Nattokinase) or even on my total anti-platelet, anti-coagulant program with the combination of Endozym and the heparin-like activity found in the oral chelator (Essential Daily Defense) or even the most comprehensive combination of those (in adequate dosages) with Omega 3, Gingko, Vitamin E etc as found in the Beyond Chelation product! Note: Lumbrokinase – Plasmin Plus – is also available and some also add this, 2 tid on top of the above, or take it in place of Nattokinase.
Please try to make your patients aware of this new and major landmark study! This report moves Coumadin finally to second fiddle and the NEW product called EXANTA to first place in the drug approach to anti-thrombotic therapies. I am NOT advocating that YOU take this but it is vital to make patients as aware as possible of all choices. Many today believe we can save one million lives a year minimum in just the United States by preventing clots, which I am convinced we are doing far better with natural products. But it is our job to give all information to our patients so that they can choose!
We have experience with patients combining the natural products, Endozym, Beyond Chelation, etc, WITH Coumadin; but some will soon be combining our natural products with the new Coumadin replacement and we HAVE NO EXPERIENCE IN THIS AREA.
However, anyone carefully looking at this study is likely to decide that with the markedly reduced risks and enhanced benefits of Exanta, which seem very clear in this study, many patients will switch soon from Coumadin and some of these may also desire to combine this new, safer, anti-coagulant with our natural protection program. The advantages for patients include no need for monitoring and 25% fewer hospitalizations for major bleeding events, which should make Exanta, replace Coumadin.
However, in my experience to date, nothing is approaching the low incidence of hospitalizations for complications and overall reduction in heart attacks and strokes that we continue to enjoy with our all-natural protocols. (Use enough of the Endozym, 5 twice daily with Beyond Chelation, which contains maximum strength Omega 3 etc., twice daily and Extra Essential Daily Defense, 2-3 with meals.) With this approach and looking at the thousands of patients now on these products, we have yet to hear of a single person being hospitalized for a bleeding complication and we continue to have tremendous success in improving health and avoiding heart attacks and strokes with this broad spectrum approach. Today, it is known that just the 1000 mg of Omega 3 with 300 EPA and 200 DHA alone taken twice daily, as these are 1 of the 9 capsules in the Beyond Chelation packets, is able to reduce and stabilize the plaque on arteries (Feb 15 2003 – Lancet).
Ximelagatran (Exanta(tm), Exanta(tm), AstraZeneca)
A recently developed, orally administered anticoagulant, Ximelagatran, has been shown to be a highly effective alternative to well-controlled warfarin for stroke prevention in patients with non-valvular Atrial fibrillation, not only resulting in a greater reduction of strokes and systemic embolic events in these individuals, but also caused less bleeding while providing a safer, easier-to-administer agent without the need for monitoring.
In the third Stroke Prevention Oral Thrombin Inhibitor in Atrial Fibrillation (SPORTIF-III trial), an open-label, randomized, non-inferiority trial, a total of 3,407 high-risk patients with Atrial fibrillation were randomized to a fixed dose of Ximelagatran, 36 mg twice daily or to warfarin, dose adjusted to an INR of between 2 and 3, the mean INR for patients in this arm being 2.5. The patients were maintained on anticoagulation therapy for 12 to 26 months. The primary objective of the study was to establish non-inferiority of Ximelagatran versus warfarin for prevention of all strokes, whether ischemic or hemorrhagic, and systemic embolic events, based on intention-to-treat.
In the intent-to-treat follow-up at 17 months, there were 56 primary events for an annual rate of 2.3% in the warfarin treatment group compared to 40 primary events for an annual rate of 1.6% in the ximelagatran-treated patients, absolute reduction favoring ximelagantran. In the on-treatment follow-up for those patients remaining on treatment for the full period of the trial, the rates of primary events were 2.2% on warfarin, with 52 strokes and embolic events versus 1.3% on Ximelagatran, with 29 primary events, a statistically relative risk reduction of 41%.
With regard to safety, there was a significant reduction in major bleeding events requiring hospitalization in the Ximelagatran group (29) compared to those in the warfarin arm (41). There was, however, an increase to greater than three times the upper limit of normal in alanine transaminase (ALT) reported in 6.5% of patients treated with Ximelagatran compared to 0.7% of those on warfarin, with all of the enzyme changes occurring within the first six months of treatment. These returned to normal, for the most part, without discontinuing Ximelagatran. (Halperin, Jonathan L. et al. 52nd Annual Scientific Session of the ACC. Late-Breaker Clinical Trial #421.